Eton Pharmaceuticals (NASDAQ:ETON) Posts Earnings Results, Hits Estimates

Eton Pharmaceuticals (NASDAQ:ETON) released its quarterly earnings data on Tuesday. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.02), Zacks reports. The company had revenue of $11.65 million for the quarter, compared to analysts’ expectations of $10.53 million. Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%.

Eton Pharmaceuticals Price Performance

ETON opened at $14.68 on Wednesday. Eton Pharmaceuticals has a fifty-two week low of $3.03 and a fifty-two week high of $18.41. The firm has a market capitalization of $382.43 million, a PE ratio of -66.73 and a beta of 1.37. The company’s 50-day moving average is $15.45 and its 200 day moving average is $11.42.

Analyst Ratings Changes

A number of research firms have recently issued reports on ETON. HC Wainwright reissued a “buy” rating and set a $33.00 price objective on shares of Eton Pharmaceuticals in a research report on Wednesday. B. Riley initiated coverage on shares of Eton Pharmaceuticals in a research report on Friday, January 10th. They set a “buy” rating and a $21.00 price objective on the stock. Finally, Craig Hallum upped their target price on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.